Stoke Therapeutics Inc (STOK)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.75B
Last updated: Nov 17, 2026 at 11:06 AM ET
Stoke Therapeutics Inc (STOK) Earnings: Report Dates and Results
Stoke Therapeutics (STOK) is expected to report earnings on Mar 15, 2027. In the quarter ended Sep 30, 2026, Stoke Therapeutics reported EPS of -$1.08, below the -$0.88 estimate. It beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
STOK has an expected report date of Mar 15, 2027.
STOK Earnings Call
The latest STOK earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 29 quarters below that had an estimate, STOK beat 17, missed 11 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $11.26M, up 5.9% from $10.63M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.08 | -$0.88 | -$1.03 - -$0.70 | -22.73% | Miss | N/A | 12 | 1 up, 3 down | Oct 29, 2026 | $11.26M |
| Jun 30, 2026 | -$0.93 | -$0.82 | -$0.94 - -$0.51 | -13.41% | Miss | N/A | 11 | 4 up, 1 down | Aug 3, 2026 | $9.32M |
| Mar 31, 2026 | -$0.79 | -$0.82 | -$0.90 - -$0.69 | +3.66% | Beat | -141.6% | 9 | 2 up, 5 down | May 7, 2026 | $6.23M |
| Dec 31, 2025 | -$0.97 | -$0.71 | -$0.86 - -$0.57 | -36.04% | Miss | N/A | 10 | 0 up, 1 down | Mar 16, 2026 | $1.40M |
| Sep 30, 2025 | -$0.65 | -$0.57 | -$0.81 - -$0.39 | -14.04% | Miss | N/A | 9 | 4 up, 3 down | Nov 4, 2025 | $10.63M |
| Jun 30, 2025 | -$0.40 | -$0.54 | -$0.72 - -$0.03 | +25.93% | Beat | N/A | 8 | 1 up, 2 down | Aug 12, 2025 | $13.82M |
| Mar 31, 2025 | $1.90 | -$0.09 | -$0.53 - $1.87 | N/A | N/A | N/A | 8 | 4 up, 0 down | May 13, 2025 | $158.57M |
| Dec 31, 2024 | -$0.18 | -$0.53 | -$0.60 - -$0.50 | +66.05% | Beat | N/A | 8 | 2 up, 0 down | Mar 18, 2025 | $22.61M |
| Sep 30, 2024 | -$0.47 | -$0.54 | -$0.60 - -$0.49 | +12.96% | Beat | N/A | 8 | 0 up, 0 down | Nov 5, 2024 | $4.89M |
| Jun 30, 2024 | -$0.46 | -$0.56 | -$0.65 - -$0.45 | +17.86% | Beat | N/A | 9 | 0 up, 1 down | Aug 7, 2024 | $4.83M |
| Mar 31, 2024 | -$0.57 | -$0.61 | -$0.70 - -$0.54 | +6.56% | Beat | N/A | 9 | 1 up, 0 down | May 6, 2024 | $4.22M |
| Dec 31, 2023 | -$0.60 | -$0.63 | -$0.71 - -$0.48 | +4.76% | Beat | N/A | 8 | 0 up, 0 down | Mar 25, 2024 | $2.80M |
| Sep 30, 2023 | -$0.55 | -$0.64 | -$0.67 - -$0.59 | +14.06% | Beat | N/A | 8 | 0 up, 0 down | Nov 7, 2023 | $3.31M |
| Jun 30, 2023 | -$0.69 | -$0.66 | -$0.72 - -$0.57 | -4.55% | Miss | N/A | 9 | 0 up, 0 down | Aug 7, 2023 | N/A |
| Mar 31, 2023 | -$0.53 | -$0.71 | -$0.76 - -$0.59 | +25.35% | Beat | N/A | 9 | 1 up, 0 down | May 4, 2023 | $5.15M |
| Dec 31, 2022 | -$0.65 | -$0.70 | -$0.77 - -$0.65 | +7.14% | Beat | N/A | 10 | 0 up, 0 down | Mar 6, 2023 | $3.27M |
| Sep 30, 2022 | -$0.66 | -$0.68 | -$0.73 - -$0.63 | +2.94% | Beat | N/A | 10 | 0 up, 0 down | Nov 14, 2022 | $2.90M |
| Jun 30, 2022 | -$0.63 | -$0.69 | N/A | +8.70% | Beat | N/A | N/A | 0 up, 0 down | Aug 8, 2022 | $3.23M |
| Mar 31, 2022 | -$0.66 | $0.13 | -$0.71 - $0.97 | -607.69% | Miss | N/A | 9 | 0 up, 0 down | May 10, 2022 | $3.00M |
| Dec 31, 2021 | -$0.66 | -$0.62 | -$0.69 - -$0.55 | -6.45% | Miss | N/A | 10 | N/A | Mar 10, 2022 | N/A |
| Sep 30, 2021 | -$0.61 | -$0.55 | -$0.70 - -$0.45 | -10.91% | Miss | N/A | 9 | N/A | Nov 8, 2021 | N/A |
| Jun 30, 2021 | -$0.60 | -$0.46 | -$0.54 - -$0.39 | -30.43% | Miss | N/A | 9 | N/A | Aug 10, 2021 | N/A |
| Mar 31, 2021 | -$0.46 | -$0.44 | -$0.48 - -$0.41 | -4.55% | Miss | N/A | 7 | N/A | May 10, 2021 | N/A |
| Dec 31, 2020 | -$0.42 | -$0.42 | -$0.46 - -$0.37 | 0.00% | In line | N/A | 8 | N/A | Mar 9, 2021 | N/A |
| Sep 30, 2020 | -$0.41 | -$0.43 | -$0.46 - -$0.38 | +4.65% | Beat | N/A | 9 | N/A | Nov 12, 2020 | N/A |
| Jun 30, 2020 | -$0.39 | -$0.36 | -$0.38 - -$0.34 | -8.33% | Miss | N/A | 6 | N/A | Aug 10, 2020 | N/A |
| Mar 31, 2020 | -$0.34 | -$0.36 | -$0.41 - -$0.31 | +5.56% | Beat | N/A | 7 | N/A | May 15, 2020 | N/A |
| Dec 31, 2019 | -$0.09 | -$0.30 | -$0.34 - -$0.27 | +70.00% | Beat | N/A | 7 | N/A | Feb 23, 2020 | N/A |
| Sep 30, 2019 | -$0.26 | -$0.28 | -$0.32 - -$0.21 | +7.14% | Beat | N/A | 5 | N/A | Nov 12, 2019 | N/A |
| Jun 30, 2019 | -$1.54 | -$1.63 | -$1.67 - -$0.21 | +5.52% | Beat | N/A | 4 | N/A | Aug 14, 2019 | N/A |
| Mar 31, 2019 | -$6.89 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 19, 2019 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.12, after -$1.68 the year before. It was -$8.78 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.12 | N/A |
| Dec 31, 2024 | -$1.68 | N/A |
| Dec 31, 2023 | -$2.37 | N/A |
| Dec 31, 2022 | -$2.60 | N/A |
| Dec 31, 2021 | -$2.33 | N/A |
| Dec 31, 2020 | -$1.56 | N/A |
| Dec 31, 2019 | -$8.78 | N/A |
Earnings Calls
The 2 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,500 words across 16 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,472 | 16 | |
| 2026Q2 | Jun 30, 2026 | 8,928 | 16 |
2026Q3 Earnings Call
Opening remarks
Thomas Leggett CFO Good evening, and welcome to Stoke Therapeutics Third Quarter 2026 Business Update Conference Call. I'm Thomas Leggett, the Chief Financial Officer at Stoke Therapeutics. Joining me on today's call are Ian Smith, our Chief Executive Officer; Dr. Barry Ticho, Chief Medical Officer; and Jason Hoitt, Chief Patient Officer. As a reminder, today's webcast presentation is available in the Investors section of our website. This webcast is being recorded and will be available for replay later this evening. Before we begin, please note that today's discussion includes forward-looking statements. These forward-looking statements are subject to risks and uncertainties, and actual results may differ materially. Please refer to our filings with the SEC for additional information. With that, I'll turn the call over to Ian.
Ian Smith CEO Thank you, Thomas, and thank you to everyone joining us this evening. It has been a busy quarter at Stoke. Tonight, we will discuss our recent progress, including an update on the advancement of patients through key time points in the EMPEROR Phase III registrational study of zorevunersen, our recent discussion with the FDA related to our NDA planning, and the latest on our commercial readiness activities. I'll start with some highlights from our Phase III study. To date, approximately 110 of the 162 enrolled patients have completed their week 28 visit. This is the time point at which data for the primary endpoint of change in major motor seizure frequency is captured. Approximately 20 patients have also completed their week 52 visit, marking the end of the study treatment period and the time point at which key secondary endpoint data will be captured. All of these patients are continuing into the open-label portion of the study. Notably, there have been no treatment discontinuations to date. Barry will provide some additional metrics and context in a few moments. Next, I will highlight our recent interaction with the FDA that gave us the opportunity to discuss our 5 years of clinical data for zorevunersen, including our Phase I/II and OLE studies, and to align on key aspects of our planned 2027 U.S. NDA submission. We were pleased with the agency's engagement, responsiveness, and interest in zorevunersen. An important outcome of our meeting was the FDA's willingness to accept a multicomponent assessment of Vineland-3 data for purposes of evaluating the key secondary endpoint related to changes in cognition and behavior. This is a positive outcome because we believe a multicomponent approach acknowledges the complexity of the disease and the fact that each patient's experience with Dravet syndrome is different, especially when it comes to impacts on cognition and behavior.
Frequently Asked Questions About STOK
When is Stoke Therapeutics's next earnings date?
Stoke Therapeutics's next earnings report is expected for Mar 15, 2027.
Did STOK beat earnings estimates last quarter?
No. Stoke Therapeutics reported EPS of -$1.08 for the quarter ended Sep 30, 2026, below the -$0.88 estimate by 22.73%.
What EPS do analysts expect from STOK next quarter?
The consensus EPS estimate for Stoke Therapeutics for the quarter ending Dec 31, 2026 is -$1.20 from 16 analysts, with estimates from -$1.31 to -$1.09.
How often does STOK beat earnings estimates?
Stoke Therapeutics beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate, with an average surprise of +2.80%.
STOK pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors